There are more and more predictions about the path that the pandemic will be taking in the near future. Now, it’s been revealed that brand new studies are addressing the efficiency of AstraZeneca’s monoclonal antibody drugs.
It’s been just revealed that the drug is effective against the civid 19 variant Omicron, according to a new report.
“The company’s EVUSHELD retains neutralization activity against omicron, according to ‘live’ virus neutralization data from both University College Oxford and Washington University School of Medicine,” ABC News reported.
The online publication Daily Wire revealed that AstraZeneca’s treatment was authorized on December 8 but used to prevent covid 19 “among people who are immune compromised, or people who are allergic to vaccine components. It is not authorized as a way to treat COVID-19 among people who have already tested positive,” ABC reported.
The reports continued and said:
“There are three monoclonal antibody treatments currently authorized to treat people who already have COVID-19. Two of those treatments — those made by Eli Lilly and Regeneron — appear to have very little activity against omicron. A third treatment, made by Vir and GlaxoSmithKline, appears to work against omicron but is currently in short supply. The companies are working to scale up production.”
Omicron covid variant
Deseret online publication notes that the Omicron variant of the coronavirus continues to spread throughout the world. People have an idea of what Omicron symptoms look like for infected people.
Now, CNN addresses the severity of covid Omicron vs the one of the Delta variant. Check out the latest reports below.
The article posted by CNN notes that the Omicron is associated with a two-thirds reduction in the risk of Covid-19 hospitalization compared with Delta, suggests one study.
This was released online Wednesday as a working paper by researchers at the University of Edinburgh in the United Kingdom.